# A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)

> **NCT07753824** · PHASE2 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Phase II
- Ivonescimab
- Intraperitoneal
- Paclitaxel
- High Grade Metastatic
- Appendiceal Adenocarcinoma

## Interventions

- **DRUG:** Ivonescimab
- **DRUG:** IP PTX

## Key facts

- **NCT ID:** NCT07753824
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-16
- **Primary completion:** 2031-11-28
- **Final completion:** 2032-11-28
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-08-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07753824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07753824, "A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07753824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*